Patent ID: 11857574
Assignee: CRISPR THERAPEUTICS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. The population of immune cells of claim 3,
wherein the CRISPR/Cas-mediated gene editing system comprises a guide RNA (gRNA) targeting a site in the Reg1 gene, wherein the target site comprises a nucleotide selected from the group consisting of SEQ ID NO: SEQ ID NO: 320, 322, 323, and 327; and/or
wherein the CRISPR/Cas-mediated gene editing system comprises a guide RNA (gRNA) targeting a site in the TGFBRII gene that comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 275, 305, 311, and 317.